$BMTI News

Last published 13y ago

13y agoBMTIBioMimetic Therapeutics, Inc. Initiates Enrollment in Augment™ Chronic Tendinopathy Clinical TrialBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it initiated enrollment in a Phase II clinical trial to assess the safety and efficacy of Augment™ Chronic Tendinopathy (ACT) as a treatment for lateral epicondylitis, commonly known as tennis elbow. The randomized, controlled trial is expected to enroll up to 100 patients at seven clinical sites in the ...
13y agoBMTI WMGIFaruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of BioMimetic Therapeutics Inc. (BMTI)Business WireNEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of BioMimetic Therapeutics Inc. (“BioMimetic” or the “Company”) (NASDAQ: BMTI) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Wright Medical Group Inc. (“WMGI”) (NASDAQ: WMGI) i ...
13y agoBMTI WMGIRigrodsky & Long, P.A. Announces Investigation Of BioMimetic Therapeutics, Inc. BuyoutBusiness WireWILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of BioMimetic Therapeutics, Inc. (“BMTI” or the “Company”) (NASDAQ GS: BMTI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Wright Medical Group, Inc. (“Wrig ...
13y agoWMGI BMTIWright Medical Group, Inc. and BioMimetic Therapeutics, Inc. Enter into Agreement to Combine BusinessesBusiness WireARLINGTON, Tenn. & FRANKLIN, Tenn.--(BUSINESS WIRE)--Wright Medical Group, Inc. (NASDAQ: WMGI) and BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that they have entered into a definitive agreement for a business combination of Wright and BioMimetic, both publicly traded, Tennessee-based companies. Wright is an orthopedics company with a market-leading lower extremities franchise. Bio ...
14y agoBMTIBioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, f ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Report Third Quarter 2012 Financial Results on November 5Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and nine months ended September 30, 2012, on Monday, November 5 after the close of market. The Company will host a conference call and audio webcast to discuss its third quarter financial results, product development programs and busin ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Present at the Wedbush PacGrow Life Sciences Management Access ConferenceBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel Lynch, president and CEO, will provide an update of corporate activities at the Wedbush PacGrow Life Sciences Management Access Conference on Wednesday, August 15th at 10:20 a.m. Eastern Daylight Time. The presentation will be held in the Gamshoge room at the Le Parker Meridien located in ...
14y agoBMTIBioMimetic Therapeutics, Inc. Reports Second Quarter 2012 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three and six months ended June 30, 2012. For the three months ended June 30, 2012, the Company reported a net loss of $6.4 million, or $0.23 per diluted share, compared to a net loss of $8.2 million, or $0.29 per diluted share, for the same ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Report Second Quarter 2012 Financial Results on August 2Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and six months ended June 30, 2012, on Thursday, August 2nd after the close of market. The Company will host a conference call and audio webcast to discuss its second quarter financial results, product development programs and business ...
14y agoBMTIBioMimetic Therapeutics Submits Augment® Bone Graft PMA Amendment to FDABusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has submitted to the Food and Drug Administration (FDA) an amendment to its Pre-Market Approval (PMA) application for Augment® Bone Graft for its use as an alternative to autograft in hindfoot and ankle fusion procedures. The amendment provides supplemental information requested by the FDA in a p ...
14y agoBMTITimothy Daniels, MD Presents Results from Augment™ Injectable Bone Graft Clinical TrialBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--Dr. Timothy Daniels, associate professor of orthopedic surgery at the University of Toronto and St. Michaels Hospital and lead investigator, presented today the results of a Canadian registration study comparing Augment™ Injectable Bone Graft (AIBG) to autograft in foot and ankle fusion surgery. Augment Injectable is an injectable bone graft developed by BioMimeti ...
14y agoBMTIPresentations from the Regenerative Strategies and Emerging Technologies Forum at the American Orthopedic Foot and Ankle Society MeetingBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--Numerous presentations were made today during the Regenerative Strategies Forum at the 2012 American Orthopaedic Foot and Ankle Society (AOFAS) annual meeting in San Diego, CA which supported the safety, effectiveness, clinical need, biologic rationale and cost effectiveness of Augment™ Bone Graft from BioMimetic Therapeutics, Inc. (NASDAQ: BMTI).
14y agoBMTIBioMimetic Therapeutics Announces Highlights from 2012 Annual Meeting of StockholdersBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the results of its 2012 Annual Meeting of Stockholders that took place on June 7, 2012, at the Company’s headquarters. The Company’s shareholders voted in favor of all proposals identified in the Proxy Statement.
14y agoBMTIBioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its corporate highlights and financial results as of and for the three months ended March 31, 2012. For the three months ended March 31, 2012, the Company reported a net loss of $6.1 million, or $0.22 per diluted share, compared to a net loss of $8.0 million, or $0.28 per diluted share, for the same perio ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Report First Quarter 2012 Financial Results on May 9Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended March 31, 2012, on Wednesday, May 9th after the close of market. The Company will host a conference call and audio webcast to discuss its first quarter financial results, product development programs and business activitie ...
14y agoBMTIBioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today reported its financial results as of and for the three and twelve months ended December 31, 2011. For the three months ended December 31, 2011, the Company reported a net loss of $9.9 million, or $0.35 per diluted share, compared to a net loss of $10.0 million, or $0.36 per diluted share, for the same period in 20 ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Report 2011 Fourth Quarter and Year-End Financial Results on March 13Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the twelve months ended December 31, 2011, on Tuesday, March 13, 2012, after market close. The Company will host a conference call and audio webcast to discuss its fourth quarter and year-end financial results, product development programs and b ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOSBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it will introduce Augmatrix™ Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, CA.
14y agoBMTIBioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS MeetingsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced results of its 30 patient Canadian Augment® Rotator Cuff Graft clinical trial. The goal of the randomized (2:1), controlled study was to assess the safety and performance of Augment Rotator Cuff for primary surgical treatment of full thickness rotator cuff tears as compared to standard surgical repair (s ...
14y agoBMTIBioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare ConferenceBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel Lynch, president and CEO, will provide an update of corporate activities at the 30th Annual J.P. Morgan Healthcare Conference on Thursday, January 12th at 10:00 a.m. Pacific Standard Time. The presentation will be held in the California East Ballroom at the Westin St. Francis located in S ...
14y agoBMTIBioMimetic Therapeutics Announces Approval to Market GEM 21S® in the European UnionBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today receipt of the CE Mark approval of GEM 21S® Growth factor Enhanced Matrix in the European Union (EU). GEM 21S was approved in the EU with broader periodontal and alveolar bone regeneration indications for use than previously approved in the U.S. and Canada. The additional indications approved in the EU a ...
14y agoBMTIBioMimetic Therapeutics Receives Augment® Bone Graft PMA Response Letter from FDABusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it received a comprehensive post-panel response letter from the FDA related to the Company's Pre-Market Approval (PMA) application for Augment® Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures. The FDA acknowledged that the independent Advisory Panel voted in ...
15y agoBMTIBioMimetic Therapeutics, Inc. Reports Third Quarter 2011 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011. For the three months ended September 30, ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Report 2011 Third Quarter Financial Results on November 8Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three and nine months ended September 30, 2011, on Tuesday, November 8 after the close of market. The Company will host a conference call and audio webcast to discuss its third quarter financial results, product development programs and busi ...
15y agoBMTIBioMimetic Therapeutics, Inc. Receives Approval to Commercialize Augment® Bone Graft in AustraliaBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Therapeutic Goods Administration (TGA) has approved the Company’s medical device application for Augment® Bone Graft clearing the way for commercialization of the product in Australia and its listing on the Australian Register of Therapeutic Goods (ARTG). Based on the clinical data from the Nort ...
15y agoBMTIThe Shuman Law Firm Investigates BioMimetic Therapeutics, Inc.Business WireBOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm today announced that it is investigating potential claims against certain officers and directors of BioMimetic Therapeutics, Inc. (“BioMimetic” or the “Company”) (NASDAQ: BMTI). BioMimetic is a biotechnology company specializing in the development and commercialization of products to promote the healing of musculoskeletal injuries and diseases.
15y agoBMTIBioMimetic Therapeutics, Inc. Reports Second Quarter 2011 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and six months ended June 30, 2011. For the three months ended June 30, 2011, the C ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Report 2011 Second Quarter Financial Results on August 4Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended June 30, 2011, on Thursday, August 4, 2011 after the close of market. The Company will host a conference call and audio webcast to discuss its second quarter financial results, product development programs and business act ...
15y agoBMTICohen Milstein Sellers & Toll PLLC Announces Investigation of BioMimetic Therapeutics, Inc.Business WireWASHINGTON--(BUSINESS WIRE)--Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether BioMimetic Therapeutics, Inc. (“BioMimetic” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
15y agoBMTIRobbins Umeda LLP Announces an Investigation of BioMimetic Therapeutics, Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at BioMimetic Therapeutics, Inc. (NASDAQ: BMTI). BioMimetic Therapeutics is a biotechnology company specializing in the development and commercialization of regenerative protein ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Present at the Wells Fargo 2011 Healthcare ConferenceBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel Lynch, president and CEO, will provide an update of corporate activities at the Wells Fargo 2011 Healthcare Conference on Wednesday, June 22nd at 3:30 p.m. Eastern Time. The presentation will be held in Adams Ballroom A at the InterContinental Boston Hotel located in Boston, Mass.
15y agoBMTIBioMimetic Therapeutics Announces Highlights from 2011 Annual Meeting of StockholdersBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today announced the results of its 2011 Annual Meeting of Stockholders that took place on June 14, 2011 at the Company’s headquarters. The Compa ...
15y agoBMTIBioMimetic Therapeutics Completes Enrollment in Augment™ Rotator Cuff Graft Pilot TrialBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported today that, ahead of previously announced guidance, the Company completed enrollment of 30 patients in a pilot clinical trial to assess ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel Lynch, president and CEO, will provide an update of corporate activities at the Jefferies Global Healthcare Conference on Thursday, June 9th at 3:30 p.m. Eastern Time. The presentation will be held in Ballroom 2 at the Grand Hyatt located in New York, New York.
15y agoBMTIBioMimetic Therapeutics’ Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory CommitteeBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, announced today that the U.S. Food & Drug Administration’s (FDA) Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Com ...
15y agoBMTIBioMimetic Therapeutics, Inc. Reports First Quarter 2011 Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three months ended March 31, 2011. For the three months ended March 31, 2011, the Company ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Present at the Deutsche Bank Healthcare ConferenceBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Larry Bullock, CFO, will provide an update of corporate activities at the 36th Annual Deutsche Bank Healthcare Conference on Tuesday, May 3 at 8:00 a.m. Eastern Time. The presentation will be held in the Hutchinson Ballroom at The InterContinental Boston in Boston, Mass.
15y agoBMTIBioMimetic Therapeutics Augment™ Bone Graft Advisory Panel Meeting Date Published in Federal RegisterBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, reported that the U.S. Food and Drug Administration (FDA) today announced plans to hold an advisory panel on Thursday, May 12 to review the Comp ...
15y agoBMTIBioMimetic Therapeutics, Inc. Reports 2010 Fourth Quarter and Year End Earnings ResultsBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and twelve months ended December 31, 2010. For the three months ended December 31, ...
15y agoBMTIBioMimetic Therapeutics to Report 2010 Fourth Quarter and Year-End Financial Results on March 10Business WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) today announced that the Company plans to release its financial results for the three and twelve months ended December 31, 2010, on Thursday, March 10, 2011 after the close of market. The Company will host a conference call and audio webcast to discuss its fourth quarter and year-end financial results, product developmen ...
15y agoBMTIBioMimetic Therapeutics, Inc. Highlights Commercial and Product Development Activities during AAOSBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery (AAOS) Annual Meeting. The BioMimetic management team provided updates regarding the Company’s May 12, 2011 Orthopedic and Rehabilitatio ...
15y agoBMTIBioMimetic Therapeutics, Inc. to Highlight Commercial and Product Development Activities during AAOSBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today announced its schedule of events during the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting being held in San Diego, CA begi ...
15y agoBMTIBioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment™ Bone GraftBusiness WireFRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative drug-device combination products to promote the healing of musculoskeletal injuries and diseases, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled an Orthopedic and Rehabilitation Device ...